Executive Summary: Workshop on Issues in the Design and Conduct of Clinical Trials of Antibacterial Drugs in the Treatment of Community-Acquired Pneumonia

摘要

For several years, the Infectious Diseases Society of America (IDSA) and its Antimicrobial Availability Task Force (AATF) have worked to reverse the decline in development of new antibacterial agents in the United States and throughout the world [ 1-4]. Economic cost-benefit considerations are one factor influencing new antibiotic development. Another is uncertainty about the proper design and conduct of clinical trials of antimicrobials so as to reliably evaluate drug safety and efficacy